We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Inhibrx Inc
3 own
4 watching
Current Price
$34.32
$-0.13
(-0.38%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,172.17M
52-Week High
39.79000
52-Week Low
14.30500
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,172.17M52-Week High39.7900052-Week Low14.30500Average Volume0.21MDividend Yield--P/E Ratio--What does the Inhibrx Inc do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Read More
How much money does Inhibrx Inc make?
News & Events about Inhibrx Inc.
PR Newswire
12 months ago
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials PR...
Zolmax
1 year ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) Analysts at Jefferies Financial Group issued their FY2024 earnings per share estimates for Inhibrx in a research report issued to clients and investors on Monday, March 6th. Jefferies Financial Group analyst M. Yee expects that the company will earn ($3.55) per...
Ticker Report
1 year ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) insider Brendan P. Eckelman sold 28,750 shares of the businesss stock in a transaction dated Wednesday, February 1st. The shares were sold at an average price of $24.73, for a total value of $710,987.50. Following the completion of the sale, the ...
Zolmax
1 year ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of the firms stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the sale, the chief executive officer now ...
Ticker Report
1 year ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of Inhibrx stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the transaction, the chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Inhibrx Inc share price today?
Can Indians buy Inhibrx Inc shares?
How can I buy Inhibrx Inc shares from India?
Can Fractional shares of Inhibrx Inc be purchased?
What are the documents required to start investing in Inhibrx Inc stocks?
What is today’s traded volume of Inhibrx Inc?
What is today’s market capitalisation of Inhibrx Inc?
What is the 52-Week High and Low Range of Inhibrx Inc?
What percentage is Inhibrx Inc down from its 52-Week High?
What percentage is Inhibrx Inc up from its 52-Week Low?
Current Price
$34.32
$-0.13
(-0.38%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.